Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPHNASDAQ:DAWNNASDAQ:DICENASDAQ:DVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$8.14-0.6%$7.95$5.15▼$10.67$1.10B1.151.34 million shs1.01 million shsDAWNDay One Biopharmaceuticals$7.08-1.5%$6.94$6.08▼$16.76$717.64M-1.31.12 million shs1.27 million shsDICEDICE Therapeutics$47.55$47.31$15.08▼$47.90$2.27B1.031.03 million shsN/ADVAXDynavax Technologies$10.28+0.4%$10.66$9.22▼$14.63$1.23B1.062.20 million shs1.37 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals0.00%+4.20%+2.37%+0.24%+54.53%DAWNDay One Biopharmaceuticals0.00%+12.52%+11.47%-10.90%-43.70%DICEDICE Therapeutics0.00%0.00%0.00%0.00%0.00%DVAXDynavax Technologies0.00%+4.38%+8.82%-28.84%-15.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals3.1517 of 5 stars3.52.00.00.03.80.81.9DAWNDay One Biopharmaceuticals1.566 of 5 stars3.60.00.00.02.02.50.0DICEDICE TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ADVAXDynavax Technologies4.541 of 5 stars3.33.00.04.72.81.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$11.5041.28% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$30.57331.80% UpsideDICEDICE Therapeutics 0.00N/AN/AN/ADVAXDynavax Technologies 2.50Moderate Buy$24.00133.46% UpsideCurrent Analyst Ratings BreakdownLatest DICE, AUPH, DVAX, and DAWN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.005/7/2025DVAXDynavax TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$33.00 ➝ $31.004/17/2025DVAXDynavax TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$12.00 ➝ $10.004/3/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.003/25/2025DAWNDay One BiopharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$39.00 ➝ $27.00(Data available from 6/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$247.30M4.45N/AN/A$2.63 per share3.10DAWNDay One Biopharmaceuticals$161.92M4.43N/AN/A$3.98 per share1.78DICEDICE Therapeutics$1.13M2,008.50N/AN/A$10.86 per share4.38DVAXDynavax Technologies$294.62M4.19N/AN/A$4.81 per share2.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals-$78.02M$0.28N/A14.54N/A-10.23%-4.41%-3.07%7/30/2025 (Estimated)DAWNDay One Biopharmaceuticals-$188.92M-$0.71N/AN/AN/AN/A-22.40%-19.79%7/8/2025 (Estimated)DICEDICE Therapeutics-$83.89M-$2.34N/AN/AN/AN/A-22.01%-20.79%N/ADVAXDynavax Technologies-$6.39M-$0.5257.1120.98N/A9.85%4.22%2.67%8/5/2025 (Estimated)Latest DICE, AUPH, DVAX, and DAWN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 million5/6/2025Q1 2025DVAXDynavax Technologies$0.03-$0.11-$0.14-$0.77$70.01 million$68.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/ADICEDICE TherapeuticsN/AN/AN/AN/AN/ADVAXDynavax TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.175.605.11DAWNDay One BiopharmaceuticalsN/A14.6214.55DICEDICE TherapeuticsN/A25.8832.44DVAXDynavax Technologies0.3313.2312.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%DAWNDay One Biopharmaceuticals87.95%DICEDICE TherapeuticsN/ADVAXDynavax Technologies96.96%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%DAWNDay One Biopharmaceuticals6.20%DICEDICE Therapeutics4.90%DVAXDynavax Technologies2.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300135.10 million137.02 millionOptionableDAWNDay One Biopharmaceuticals60101.36 million92.38 millionOptionableDICEDICE Therapeutics7147.73 million45.39 millionNot OptionableDVAXDynavax Technologies350120.08 million127.54 millionOptionableDICE, AUPH, DVAX, and DAWN HeadlinesRecent News About These CompaniesDeep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the BoardroomJune 9 at 1:23 PM | finance.yahoo.comDeep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final ...June 9 at 9:11 AM | gurufocus.comDeep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final ...June 9 at 9:11 AM | gurufocus.comDeep Track Capital Pushes for Board Changes at Dynavax Technologies Corp (DVAX) | DVAX stock newsJune 9 at 9:11 AM | gurufocus.comDynavax Technologies Corp (DVAX) Urges Stockholders to Support Director Nominees | DVAX stock newsJune 9 at 8:20 AM | gurufocus.comDynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual MeetingJune 9 at 7:30 AM | prnewswire.comEquities Analysts Offer Predictions for DVAX FY2027 EarningsJune 8 at 1:43 AM | americanbankingnews.comFY2027 Earnings Forecast for DVAX Issued By William BlairJune 6 at 7:01 AM | marketbeat.comEquities Analysts Issue Forecasts for DVAX FY2028 EarningsJune 6 at 1:47 AM | americanbankingnews.comVaccine maker Dynavax's future hangs in balance amid activist investor showdownJune 5, 2025 | bizjournals.comFY2028 Earnings Estimate for DVAX Issued By William BlairJune 5, 2025 | marketbeat.comGlass Lewis Recommends Shareholders Support Deep Track’s Case for Board Change at Dynavax TechnologiesJune 5, 2025 | finance.yahoo.comGlass Lewis backs two of Deep Track's four nominees in Dynavax fightJune 5, 2025 | msn.comDynavax Comments on Glass Lewis RecommendationJune 4, 2025 | prnewswire.comGlass Lewis Recommends Shareholders Support Deep Track's Case for Board Change at Dynavax TechnologiesJune 4, 2025 | businesswire.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $5.37 Million Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)June 3, 2025 | marketbeat.comDynavax Technologies Co. (NASDAQ:DVAX) Short Interest Down 21.8% in MayJune 2, 2025 | marketbeat.comMillennium Management LLC Has $2.33 Million Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)June 2, 2025 | marketbeat.comSquarepoint Ops LLC Increases Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)May 31, 2025 | marketbeat.comTwo Sigma Advisers LP Has $1.72 Million Position in Dynavax Technologies Co. (NASDAQ:DVAX)May 31, 2025 | marketbeat.comJefferies Financial Group Inc. Makes New $2.46 Million Investment in Dynavax Technologies Co. (NASDAQ:DVAX)May 29, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDICE, AUPH, DVAX, and DAWN Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$8.14 -0.05 (-0.61%) Closing price 04:00 PM EasternExtended Trading$8.13 -0.01 (-0.07%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Day One Biopharmaceuticals NASDAQ:DAWN$7.08 -0.11 (-1.53%) Closing price 04:00 PM EasternExtended Trading$7.08 +0.00 (+0.07%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.DICE Therapeutics NASDAQ:DICEDICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.Dynavax Technologies NASDAQ:DVAX$10.28 +0.04 (+0.39%) Closing price 04:00 PM EasternExtended Trading$10.28 +0.01 (+0.05%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Science Applications International Is a Wicked Hot Buy in June Why Unity Software May Be the AI Breakout No One Saw Coming Tesla Stock Dips to Buy Zone—Robotaxi Catalyst Ahead? Is Lululemon’s 18% Selloff Overdone? Analysts Say Yes MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
